Investment Thesis: The 10x Transformation
.png/:/cr=t:0%25,l:0%25,w:100%25,h:100%25/rs=w:400,cg:true)
We are not just building a tool; we are building the infrastructure for a data-driven healthcare future. Our platform decouples clinical revenue from manual labor, transforming high-latency medical services into high-margin software outputs.
Current Vertical: Sleep Diagnostic Scoring (Automated PSG Analysis).
The Delta: Reducing manual scoring from 2-4 hours to under 5 minutes.
Infrastructure: SOC 2 Type II compliant, cloud-native backbone via Nuvollo.
Validation: Strategic partnership with MedSleep Inc. for clinical scaling.
Regulatory Roadmap: The Path to Global Clearance
Phase 1: Infrastructure & Quality Systems (Months 0–6)
Phase 4: Vertical Expansion & Global Scaling (Months 18–24+)
Phase 2: Clinical Validation & Peer Review (Months 6–12)
Focus: Building the Institutional Backbone
- ISO 13485:2016 Certification: Implementation of a comprehensive Quality Management System (QMS) tailored for AI-driven diagnostics.
- SOC 2 Type II Finalization: Leveraging our Nuvollo partnership to ensure the diagnostic engine meets the highest global standards for data sovereignty and cybersecurit
Focus: Building the Institutional Backbone
- ISO 13485:2016 Certification: Implementation of a comprehensive Quality Management System (QMS) tailored for AI-driven diagnostics.
- SOC 2 Type II Finalization: Leveraging our Nuvollo partnership to ensure the diagnostic engine meets the highest global standards for data sovereignty and cybersecurity.
- IEC 62304 Compliance: Establishing life-cycle requirements for our medical device software to ensure safe and repeatable code deployment.
Phase 2: Clinical Validation & Peer Review (Months 6–12)
Phase 4: Vertical Expansion & Global Scaling (Months 18–24+)
Phase 2: Clinical Validation & Peer Review (Months 6–12)
Focus: Strengthening the "Gold Standard" Proof
- MedSleep Pilot Expansion: Completing multi-site clinical validation to solidify the 84.5% accuracy metrics across diverse patient demographics.
- Peer-Reviewed Publication: Submission of validation data to leading sleep medicine journals (e.g., Journal of Clinical Sleep Medicine).
- Investor Note:
Focus: Strengthening the "Gold Standard" Proof
- MedSleep Pilot Expansion: Completing multi-site clinical validation to solidify the 84.5% accuracy metrics across diverse patient demographics.
- Peer-Reviewed Publication: Submission of validation data to leading sleep medicine journals (e.g., Journal of Clinical Sleep Medicine).
- Investor Note: This is a critical trust signal that moves the product from "software" to "science."
- Pivotal Study Initiation: Launching the final clinical trial required for formal regulatory submission.
Phase 3: Market Authorization & Clearance (Months 12–18)
Phase 4: Vertical Expansion & Global Scaling (Months 18–24+)
Phase 4: Vertical Expansion & Global Scaling (Months 18–24+)
Focus: Achieving Formal Market Entry
- FDA 510(k) Submission (USA): Filing as a Class II Software as a Medical Device (SaMD) for automated sleep scoring.
- Health Canada Class II License: Parallel submission to capture the North American market, leveraging the MedSleep partnership for Canadian clinical proof.
- HIPAA / GDPR Audit: Finalizing juris
Focus: Achieving Formal Market Entry
- FDA 510(k) Submission (USA): Filing as a Class II Software as a Medical Device (SaMD) for automated sleep scoring.
- Health Canada Class II License: Parallel submission to capture the North American market, leveraging the MedSleep partnership for Canadian clinical proof.
- HIPAA / GDPR Audit: Finalizing jurisdictional privacy audits to support seamless global data handling.
Phase 4: Vertical Expansion & Global Scaling (Months 18–24+)
Phase 4: Vertical Expansion & Global Scaling (Months 18–24+)
Phase 4: Vertical Expansion & Global Scaling (Months 18–24+)
Focus: Transitioning to a Multi-Vertical Platform
- CE Mark (MDR) Submission: Initiating European market entry protocols.
- Cardiac Ultrasound (Echocardiography) Pilot: Utilizing Proprietary Signal Transferability to begin the regulatory pathway for our second diagnostic vertical.
- Post-Market Surveillance: Implementing real-time AI performance m
Focus: Transitioning to a Multi-Vertical Platform
- CE Mark (MDR) Submission: Initiating European market entry protocols.
- Cardiac Ultrasound (Echocardiography) Pilot: Utilizing Proprietary Signal Transferability to begin the regulatory pathway for our second diagnostic vertical.
- Post-Market Surveillance: Implementing real-time AI performance monitoring to maintain accuracy and safety as the platform scales to 1,000+ labs.
Use of Series A Capital
Engineering Hub ($1.08M)
Regulatory & Clinical ($1.29M)
Infrastructure ($480,000)
Onshoring 4 senior specialists in Toronto to harden the "Physician Co-Pilot" and ensure 99.9% uptime for the MedSleep contract.
Infrastructure ($480,000)
Regulatory & Clinical ($1.29M)
Infrastructure ($480,000)
Scaling GPU density and cloud inference engines to drop per-study costs to near-zero, maximizing 80%+ gross margins.
Regulatory & Clinical ($1.29M)
Regulatory & Clinical ($1.29M)
Regulatory & Clinical ($1.29M)
Finalizing FDA 510(k) and Health Canada filings to become the legally cleared "Gold Standard" in North America.
Institutional Trust & Compliance
Data Sovereignty
Institutional Oversight
Verified Accuracy
Ascend Aegis ensures total data sovereignty through full compliance with global healthcare standards. Our Nuvollo-powered infrastructure provides mission-critical security and jurisdictional integrity, de-risking international expansion. This foundation offers a secure, scalable architecture engineered for high-fidelity, worldwide diagnostic deployment.
Verified Accuracy
Institutional Oversight
Verified Accuracy
Aegis delivers a consistent 84.5% agreement with human-scored gold standards, eliminating subjective manual variability. This verified accuracy, backed by explainable AI transparency, builds institutional trust. We provide the high-fidelity precision necessary to standardize clinical outcomes and scale diagnostic automation globally.
Institutional Oversight
Institutional Oversight
Institutional Oversight
Led by Dr. Stephen Glazer, our regular clinical validation sessions ensure the highest standards of integrity. By bridging AI performance with expert medical oversight, we provide transparent, high-fidelity results. This integrity-driven leadership de-risks deployment and builds lasting institutional trust.